Epidemiological investigation on cardiometabolic abnormalities in Songnan Community residents with type 2 diabetes

doi:10.16150/j.1671-2870.2019.03.015

Abstract

Abstract:

Objective: To investigate the prevalence of cardiometabolic abnormalities and the association between the risk factors and cardiometabolic abnormalitiesin community residents with type 2 diabetes. Methods: A cross-sectional study was conducted among 1 322 diabetic adults aged 40 years in Songnan district, Shanghai in 2009. Clinical data, anthropometric measurements, and results of biochemical analysis were collected, and participants were categorized into male and female and divided into three groups according to the number of cardiometabolic abnormalities present (including general obesity or abdominal obesity, hypertension, dyslipidemia, albuminuria, elevated CIMT_max): group 1 (0-2 abnormality), group 2 (3 abnormalities), and group 3(4-5 abnormalities), to analyze the association between risk factors such as age, sex, glycated hemoglobin and cardiometabolic abnormalities. Results: Of the 1 322 type 2 diabetic patients, there were 501 men and 731 women, average age was (64.1±9.8) years. Ratios of cardiometabolic abnormalities in male vs. female diabetic patients were 9.8% vs. 17.4% (general obesity); 57.5% vs. 69.6% (abdominal obesity); 72.9% vs. 76.6% (hypertension); 50.1% vs. 55.3% (dyslipidemia); 26.4% vs. 23.9% (albuminuria); 19.1% vs.12.0% (elevated CIMT_max). Multiple logistic regression analysis showed that increasing age, high serum HbA1c and C reactive protein levels, current smoking,and insulin resistance were risk factors of associated cardiometabolic abnormalities(all P<0.05). Conclusions: A high prevalence of cardiometabolic abnormalities existed in community residents with type 2 diabetes in Songnan district, Shanghai.Increasing age, high serum HbA1c and C reactive protein levels, current smoking, and insulin resistance are correlated with the increase of associated cardiometabolic abnormalities.

Key words: Diabetes, Cardiometabolic abnormalities, Epidemiology

CLC Number:

R541.4

LIU Shanshan, Niu Jingya, WANG Tiange, LI Mian, ZHAO Zhiyun, XU Yu, LU Jieli, XU Min, BI Yufang, ZHANG Di. Epidemiological investigation on cardiometabolic abnormalities in Songnan Community residents with type 2 diabetes[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(03): 323-328.

Figures/Tables 4

References 26

[1]	Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013[J]. Lancet. 2016 Jan 16; 387(10015):251-272. doi: 10.1016/S0140-6736(15)00551-6 URL
[2]	Tian Y, Jiang C, Wang M, et al. BMI, leisure-time physical activity, and physical fitness in adults in China: results from a series of national surveys, 2000-14[J]. Lancet Diabetes Endocrinol, 2016, 4(6):487-497. doi: 10.1016/S2213-8587(16)00081-4 URL
[3]	Patel SA, Winkel M, Ali MK, et al. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data[J]. Ann Intern Med, 2015, 163(4):245-253.
[4]	Niskanen L, Turpeinen A, Penttilä I, et al. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis[J]. Diabetes Care, 1998, 21(11):1861-1869. pmid: 9802734
[5]	Eckel RH, York DA, Rössner S, et al. Prevention Con-ference Ⅶ: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary[J]. Circula-tion, 2004, 110(18):2968-2975.
[6]	Wohlin M, Sundström J, Arnlöv J, et al. Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men[J]. Atherosclerosis, 2003, 170(1):181-185. pmid: 12957698
[7]	Si Y, Zhou Z, Su M, et al. Catastrophic healthcare expenditure and its inequality for households with hypertension: evidence from the rural areas of Shaanxi Province in China[J]. Int J Equity Health, 2017, 16(1):27. doi: 10.1186/s12939-016-0506-6 URL
[8]	GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1 URL
[9]	Gordon-Dseagu VL, Shelton N, Mindell J. Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease: evidence from the Health Survey for England and Scottish Health Survey cohorts[J]. J Diabetes Complications, 2014, 28(6):791-797. doi: 10.1016/j.jdiacomp.2014.06.016 URL
[10]	陆赵阳, 金建文. 糖尿病高血压患者颈动脉中内膜厚度的分析[J]. 浙江临床医学, 2016, 18(9):1700-1701.
[11]	杨历新, 张亚萍, 孙海霞, 等. 不同糖代谢人群颈动脉粥样硬化的研究[J]. 中华老年心脑血管病杂志, 2007, 9(3):170-172.
[12]	屈宁宁, 李可基. 国际体力活动问卷中文版的信度和效度研究[J]. 中华流行病学杂志, 2004, 25(3):265-268.
[13]	Yuan C, Lai CW, Chan LW, et al. Cumulative effects of hypertension, dyslipidemia, and chronic kidney disease on carotid atherosclerosis in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2014, 2014:179686.
[14]	秦方, 张廷杰, 阮蕾, 等. 糖尿病合并高血压现状及其影响-成都7 288例人群分析[J]. 高血压杂志, 2002, 10(1):91-93.
[15]	Martinez-Hervas S, Carmena R, Ascaso JF, et al. Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: the di@bet.es study[J]. Clin Investig Arterioscler, 2014, 26(3):107-114. doi: 10.1016/j.arteri.2013.12.001 pmid: 24461346
[16]	Yan L, Xu MT, Yuan L, et al. Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China[J]. J Clin Lipidol, 2016, 10(1):150-160. doi: 10.1016/j.jacl.2015.10.009 pmid: 26892132
[17]	Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type Ⅱ diabetic patients: a global perspective[J]. Kidney Int, 2006, 69(11):2057-2063. pmid: 16612330
[18]	付翰林, 王新良, 王婷婷, 等. 浏阳市成年居民2型糖尿病合并高血压的危险因素[J]. 中南大学学报(医学版), 2015, 40(12):1384-1390.
[19]	李青, 包玉倩, 张磊, 等. 中年2型糖尿病住院患者微量白蛋白尿的发生率及危险因素分析[J]. 上海医学, 2009, 32(5):384-387.
[20]	涂燕平, 雷梦觉, 曾黎峰, 等. 糖尿病患者颈动脉内膜中层厚度及血清C-反应蛋白检测的临床意义[J]. 中国临床保健杂志, 2005, 8(6):496-497.
[21]	Bruno CM, Meli S, Marcinno M, et al. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients[J]. J Biol Regul Homeost Agents, 2002, 16(2):114-117.
[22]	Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences[J]. J Clin Hypertens (Greenwich), 2011, 13(4):238-243. doi: 10.1111/j.1751-7176.2011.00439.x URL
[23]	Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988[J]. Nutrition. 1997 Jan; 13(1):64-66.
[24]	Cohn JS, Patterson BW, Uffelman KD, et al. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-Ⅲ is strongly related to the concentration and level of production of VLDL triglyce-ride in male subjects with different body weights and levels of insulin sensitivity[J]. J Clin Endocrinol Metab, 2004, 89(8):3949-3955. doi: 10.1210/jc.2003-032056 URL
[25]	撒小军, 张永明, 宋洁, 等. 2型糖尿病患者外周血血小板/淋巴细胞比值与肾小球滤过率的相关性分析[J]. 安徽医学, 2019, 40(5):543-546.
[26]	Hamrefors V, Hedblad B, Hindy G, et al. Smoking modifies the associated increased risk of future cardiovascular disease by genetic variation on chromosome 9p21[J]. PLoS One, 2014, 9(1):e85893. doi: 10.1371/journal.pone.0085893 URL

变量	男性（n=591）	女性（n=731）	P值
年龄（岁）	62.9±9.8	64.1±9.8	0.026 5
受教育年限≥9年[n（%）]	472(79.9)	409(56.0)	<0.000 1
糖尿病家族史[n（%）]	155(26.2)	233(31.9)	0.025 0
糖尿病病程（年）	1.3(0~7.0)	2.1(0~8.3)	0.782 8
当前吸烟[n(%)]	245(41.5)	19(2.6)	<0.000 1
当前饮酒[n(%)]	195(33.0)	25(3.4)	<0.000 1
体力活动（MET-h/wk）	23.1(11.6~46.2)	23.1(11.6~46.2)	0.718 8
腰围（cm）	91.2±8.9	90.0±10.2	0.019 7
臀围（cm）	97.6±6.9	97.3±8.5	0.409 3
体质量指数（kg/m²）	25.8±3.4	26.7±4.3	<0.000 1
收缩压（mmHg）	144.6±20.2	149.2±22.9	0.000 1
舒张压（mmHg）	81.7±10.2	78.5±10.2	<0.000 1
三酰甘油（mmol/L）	1.57(1.11~2.48)	1.78(1.29~2.58)	0.049 4
高密度脂蛋白胆固醇（mmol/L）	1.23±0.27	1.36±0.29	<0.000 1
低密度脂蛋白胆固醇（mmol/L）	2.32±0.72	2.48±0.75	<0.000 1
总胆固醇（mmol/L）	4.97±1.00	5.45±1.13	<0.000 1
空腹血糖（mmol/L）	7.52±2.60	7.56±2.63	0.761 2
2 h血糖（mmol/L）	16.40±4.52	16.79±5.80	0.169 4
糖化血红蛋白（%）	7.6(6.6~9.0)	7.4(6.6~8.5)	0.099 2
空腹胰岛素（μIU/L）	7.56(5.10~11.73)	10.27(7.09~15.61)	<0.000 1
2 h胰岛素（μIU/L）	44.77(24.97~71.20)	60.53(35.93~102.20)	<0.000 1
胰岛素抵抗指数	2.50(1.57~3.91)	3.24(2.11~5.32)	<0.000 1
C反应蛋白（mg/L）	0.32(0.09~1.21)	0.51(0.14~1.91)	<0.000 1
尿蛋白肌酐比（mg/g）	7.25(2.97~17.78)	8.18(3.72~23.71)	0.003 8
CIMT_max（mm）	0.7 (0.6~0.8)	0.6 (0.6~0.8)	<0.000 1

变量	0~2个（734例）	3个（384例）	4~5个（204例）	趋势P值
男性	338(46.1)	162(42.2)	91(44.6)	0.452 5
年龄（岁）	62.3±9.4	64.6±9.6	66.1±10.6	<0.000 1
受教育年限≥9年	514(70.0)	246(64.1)	121(59.3)	0.001 7
糖尿病家族史	233(31.7)	90(23.4)	65(31.9)	0.310 4
糖尿病病程（年）	4.7±6.3	4.2±5.5	5.2±6.6	0.481 3
当前吸烟[n(%)]	141(19.2)	79 (20.6)	44(21.6)	0.411 9
当前饮酒[n(%)]	119(16.2)	68(17.7)	33(16.2)	0.826 5
体力活动（MET-h/wk）	23.1(11.6~46.2)	23.1(11.6~46.2)	23.1(11.6~46.2)	0.641 4
糖化血红蛋白（%）	7.3(6.5~8.6)	7.5(6.8~8.7)	7.9(6.9~9.3)	<0.000 1
胰岛素抵抗[n(%)]	354(48.2)	258(67.2)	158(77.5)	<0.000 1
C反应蛋白（mg/L）	0.25(0.08~1.01)	0.57(0.17~1.78)	1.18(0.37~4.17)	<0.000 1

危险因素	3 个（384例）OR（95% CI）	P值	4~5个（204例）OR（95% CI）	P值
男性比女性	0.75（0.54~1.03）	0.074 2	0.92（0.61~1.37）	0.668 0
年龄（增加10岁）	1.37（1.16~1.62）	0.000 2	1.64（1.33~2.03）	<0.000 1
受教育年限≥9年	1.10（0.79~1.53）	0.593 7	0.96（0.63~1.45）	0.844 7
糖尿病家族史	0.76（0.56~1.03）	0.088 3	1.24（0.85~1.82）	0.268 5
糖尿病病程≥10年	0.97（0.95~0.99）	0.006 4	0.99（0.96~1.02）	0.402 3
当前吸烟	1.43（0.98~2.09）	0.067 2	1.77（1.09~2.88）	0.022 1
当前饮酒	1.38（0.94~2.02）	0.098 3	1.11（0.68~1.81）	0.688 3
体力活动（增加1 MET-h/wk）	1.00（1.00~1.00）	0.320 6	1.00（1.00~1.00）	0.973 4
糖化血红蛋白≥6.5%	1.78（1.25~2.55）	0.001 5	1.62（0.99~2.66）	0.056 2
胰岛素抵抗	1.78（1.37~2.32）	<0.000 1	3.68（2.56~5.27）	<0.000 1
C反应蛋白（增加1 mg/L）	1.02（1.00~1.03）	0.083 1	1.02（1.00~1.04）	0.021 1